Low molecular weight heparin dosing and monitoring in solid organ transplant recipients.

about

Evaluation of Enoxaparin Dosing as a Risk Factor for Bleeding in Lung Transplant Recipients.Prophylaxis with enoxaparin for prevention of venous thromboembolism after lung transplantation: a retrospective study.

P2860

Q40673191-398BB040-123D-4EAE-9967-84FB244DE81C Q48249771-7B4E65E9-CF43-4115-91F9-150D0008419D

P2860

Low molecular weight heparin dosing and monitoring in solid organ transplant recipients.

Item

http://www.wikidata.org/entity/Q38137244

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Low molecular weight heparin dosing and monitoring in solid organ transplant recipients.

@en

type

Item

label

Low molecular weight heparin dosing and monitoring in solid organ transplant recipients.

@en

prefLabel

Low molecular weight heparin dosing and monitoring in solid organ transplant recipients.

@en

P1476

Low molecular weight heparin dosing and monitoring in solid organ transplant recipients.

@en

P2093

A Osama Gaber

http://www.w3.org/2001/XMLSchema#string

David Putney

http://www.w3.org/2001/XMLSchema#string

Misbah A Moten

http://www.w3.org/2001/XMLSchema#string

Samir J Patel

http://www.w3.org/2001/XMLSchema#string

P2860

Executive summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines

Influence of patient characteristics and renal function on factor Xa inhibition pharmacokinetics and pharmacodynamics after enoxaparin administration in non-ST-segment elevation acute coronary syndromes

Chronic renal failure after transplantation of a nonrenal organ

Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency.

Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis.

Comparative pharmacokinetics of LMWHs.

Wait list death and survival benefit of kidney transplantation among nonrenal transplant recipients

Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.

Supratherapeutic anticoagulation from low-molecular-weight heparin in lung transplant recipients.

Dosing practices and risk factors for bleeding in patients receiving enoxaparin for the treatment of an acute coronary syndrome.

P304

852-857

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/CTR.12240

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2013-09-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24033530

http://www.w3.org/2001/XMLSchema#string

Low molecular weight heparin dosing and monitoring in solid organ transplant recipients.

about

P2860

P2860

Low molecular weight heparin dosing and monitoring in solid organ transplant recipients.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698